Pharmaceutical industry

Gilead Sciences to Release First Quarter 2021 Financial Results on Thursday, April 29, 2021

Thursday, April 15, 2021 - 9:05pm

b'Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2021 financial results will be released on Thursday, April 29, after the market closes.

Key Points: 
  • b'Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2021 financial results will be released on Thursday, April 29, after the market closes.
  • At 4:30 p.m. Eastern Time, Gilead\xe2\x80\x99s management will host a conference call to discuss the company\xe2\x80\x99s first quarter 2021 financial results and will provide a business update.\nA live webcast of the call can be accessed at Gilead\xe2\x80\x99s Investors page at http://investors.gilead.com , or by dialing 1-877-359-9508 (U.S.) or 1-224-357-2393 (international) with conference ID 5069935.
  • The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer.
  • Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.\nFor more information on Gilead Sciences, please visit the company\xe2\x80\x99s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210415005950/en/\n'

My Intelligent Machines Inc. Secures $5 Million in Seed Financing to Support International Sales and Growing Capabilities

Thursday, April 15, 2021 - 4:14pm

b"My Intelligent Machines Inc. (\xe2\x80\x9cMIMs\xe2\x80\x9d), a leader in artificial intelligence and systems biology, today announced that it has completed an equity financing of $5 million.

Key Points: 
  • b"My Intelligent Machines Inc. (\xe2\x80\x9cMIMs\xe2\x80\x9d), a leader in artificial intelligence and systems biology, today announced that it has completed an equity financing of $5 million.
  • We can provide a better understanding of patient heterogeneity with respect to both disease and response to treatment.
  • Our platform enables the identification of targets for drugs with increased efficacy, prioritization of indications at pre-clinical stages and reduction of clinical trial failure rate,\xe2\x80\x9d said Sarah Jenna, Ph.D., co-founder and CEO of My Intelligent Machines.
  • In late 2020, MIMs received the Red Herring\xe2\x80\x99s Top 100 North America Award, one of the most prestigious prizes granted each year to the most promising private tech companies.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210415005755/en/\n"

Global Generic Drugs (Small Molecule Generics vs Biosimilars) Market Forecast & Opportunities, 2021-2026 by Application, Drug Delivery, Form, Source, Distribution Channel - ResearchAndMarkets.com

Thursday, April 15, 2021 - 4:03pm

b'The "Global Generic Drugs Market, By Type (Small Molecule Generics vs Biosimilars), By Application (Cardiovascular Diseases, Diabetes, Neurology, Others), By Drug Delivery, By Form, By Source, By Distribution Channel, By Company, By Region, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe Global Generic Drugs Market was valued at USD371.04 billion in 2020 and is anticipated to reach USD564.43 billion until 2026 by witnessing a CAGR of 7.08% during the forecast period.\nThe Global Generic Drugs Market is driven by rising prevalence of chronic diseases across the globe.

Key Points: 
  • b'The "Global Generic Drugs Market, By Type (Small Molecule Generics vs Biosimilars), By Application (Cardiovascular Diseases, Diabetes, Neurology, Others), By Drug Delivery, By Form, By Source, By Distribution Channel, By Company, By Region, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe Global Generic Drugs Market was valued at USD371.04 billion in 2020 and is anticipated to reach USD564.43 billion until 2026 by witnessing a CAGR of 7.08% during the forecast period.\nThe Global Generic Drugs Market is driven by rising prevalence of chronic diseases across the globe.
  • Moreover, availability of generic drugs at a lower cost and having the same chemical composition of branded drugs is one of the key factors which is positively impacting the growth of the market during the forecast period.
  • Also, increasing count of drug patent expirations is further expected to bolster the growth of the market over the next few years.\nThe Global Generic Drugs Market is segmented based on type, application, drug delivery, form, source, distribution channel, company, and region.
  • Other competitive strategies include mergers & acquisitions, partnership, agreements, and new developments in order to expand their geographic reach and to increase their customer base.\nTo analyze historical growth in market size of the Global Generic Drugs Market from 2016 to 2019.\nTo estimate and forecast the market size of the Global Generic Drugs Market from 2021 to 2026 and growth rate until 2026.\nTo classify and forecast the Global Generic Drugs Market based on type, application, drug delivery, form, source, distribution channel, company and regional distribution.\nTo identify dominant region or segment in the Global Generic Drugs Market.\nTo identify drivers and challenges for the Global Generic Drugs Market.\nTo examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the Global Generic Drugs Market.\nTo conduct pricing analysis for the Global Generic Drugs Market.\nTo identify and analyze the profiles of leading players operating in the Global Generic Drugs Market.\nTo identify key sustainable strategies adopted by market players in the Global Generic Drugs Market.\nYears considered for this report:\n'

Worldwide Topical Pain Relief Industry to 2025 - by Therapeutic Class, Mode of Purchase and Region - ResearchAndMarkets.com

Thursday, April 15, 2021 - 1:15pm

b'Analyses of the global market trends, with data from 2019 and 2020, and projections of compound annual growth rates (CAGRs) through 2025\nExamination of the competitive environment, regulatory scenario and technological advancements which are influencing the growth of generic drugs market\nProfiles of the leading market players, including GlaxoSmithKline, Sanofi S.A., Johnson & Johnson, Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd.\nGrowth of the global market is attributed to factors such as the growing prevalence of cancer, diabetes and other chronic diseases; and strong investment in research and development activities by key market players including GlaxoSmithKline, SanofiS.A., Johnson& Johnson, SunPharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd., among others.\nThe increasing incidence of acute and chronic pain and rising geriatric populations with osteoporosis-related issues are the major factors likely to fuel the market for topical pain management drugs.\nAccording to the Global Burden of Disease Study 2016, the high prominence of pain and pain-related diseases is the leading cause of disability and disease burden globally.

Key Points: 
  • b'Analyses of the global market trends, with data from 2019 and 2020, and projections of compound annual growth rates (CAGRs) through 2025\nExamination of the competitive environment, regulatory scenario and technological advancements which are influencing the growth of generic drugs market\nProfiles of the leading market players, including GlaxoSmithKline, Sanofi S.A., Johnson & Johnson, Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd.\nGrowth of the global market is attributed to factors such as the growing prevalence of cancer, diabetes and other chronic diseases; and strong investment in research and development activities by key market players including GlaxoSmithKline, SanofiS.A., Johnson& Johnson, SunPharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd., among others.\nThe increasing incidence of acute and chronic pain and rising geriatric populations with osteoporosis-related issues are the major factors likely to fuel the market for topical pain management drugs.\nAccording to the Global Burden of Disease Study 2016, the high prominence of pain and pain-related diseases is the leading cause of disability and disease burden globally.
  • In 2016, the burden of chronic pain increased, with 1.9 billion people with symptomatic chronic conditions.
  • The burden of chronic pain is likely to drive the market for topical pain management drugs during the forecast period.\nThe global topical pain management drugs market is segmented based on therapeutic class, mode of purchase and region.\n'

Medable Secures Another $78 Million Funding to Fuel Digital Innovation for Patient-Centered Drug Development

Thursday, April 15, 2021 - 12:37pm

b'Medable Inc. today announced $78 million in new funding to fuel advances in the delivery of digital and decentralized clinical trials, accelerating the industry\xe2\x80\x99s shift to patient-centered drug development.

Key Points: 
  • b'Medable Inc. today announced $78 million in new funding to fuel advances in the delivery of digital and decentralized clinical trials, accelerating the industry\xe2\x80\x99s shift to patient-centered drug development.
  • Medable will use the funding to continue enabling broad adoption of digital trials and patient-centric strategies at global scale.
  • By minimizing the need for in-person site visits, Medable customers have achieved unprecedented results \xe2\x80\x93 including 3X faster enrollment and over 90 percent retention rates.
  • \xe2\x80\x9cMedable is committed to delivering the leading solutions to drug developers for this incredibly important change in how clinical research is conducted.

Aceto Strengthens Self-Manufacturing and Vaccine and Biopharmaceutical Offering With Acquisition of A&C

Thursday, April 15, 2021 - 2:30pm

With A&C, Aceto now provides customers greater access to critical raw materials and excipients used in synthesizing biologics, as well as enhanced support throughout the drug development process.\n\xe2\x80\x9cWith the acquisition of A&C, Aceto has materially expanded its self-manufactured and custom product offerings in the vaccine and biopharmaceutical space,\xe2\x80\x9d said Gilles Cottier, Chief Executive Officer of Aceto.

Key Points: 
  • With A&C, Aceto now provides customers greater access to critical raw materials and excipients used in synthesizing biologics, as well as enhanced support throughout the drug development process.\n\xe2\x80\x9cWith the acquisition of A&C, Aceto has materially expanded its self-manufactured and custom product offerings in the vaccine and biopharmaceutical space,\xe2\x80\x9d said Gilles Cottier, Chief Executive Officer of Aceto.
  • With business operations in nine countries, Aceto distributes over 1,100 chemical compounds used principally by the pharmaceutical, nutraceutical, agricultural, and specialty chemical industries.
  • www.aceto.com\nA&C is a global GMP manufacturer of excipients, buffers, process solutions and a select number of active pharmaceutical ingredients (APIs).
  • A&C is committed to providing certified GMP products in full compliance with international regulatory requirements to meet customers\xe2\x80\x99 needs globally.\n"

Proxima Clinical Research Experiences Fast Growth Following Brief Covid-19 Dip

Thursday, April 15, 2021 - 3:37pm

b'Proxima Clinical Research (\xe2\x80\x9cProxima CRO\xe2\x80\x9d), a contract research organization (CRO) based out of the Texas Medical Center in Houston, announced today it has experienced tremendous growth in clients, clinical studies, and new hires in the last half of CY 2020 and first quarter of CY 2021.

Key Points: 
  • b'Proxima Clinical Research (\xe2\x80\x9cProxima CRO\xe2\x80\x9d), a contract research organization (CRO) based out of the Texas Medical Center in Houston, announced today it has experienced tremendous growth in clients, clinical studies, and new hires in the last half of CY 2020 and first quarter of CY 2021.
  • In CYQ4 2020 alone, the company signed a new client every three days, onboarding 30 clients in 90 days.
  • \xe2\x80\x9cWe designed Proxima to be the premiere clinical and regulatory resource to support the new class of rising stars in drugs, devices, diagnostics, and digital healthcare products.
  • Launched in November 2017, Proxima CRO is a registered Delaware C Corporation.\nFor more on Proxima CRO and its growing team, visit ProximaCRO.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210415005152/en/\n'

Axial Therapeutics to Present at Virtual Jefferies Microbiome-based Therapeutics Summit

Thursday, April 15, 2021 - 1:00pm

b'Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. Stewart Campbell, Ph.D., chief executive officer, will present an overview of the company and take part in one-on-one meetings with institutional investors at the Jefferies Microbiome-based Therapeutics Summit on April 22, 2021.

Key Points: 
  • b'Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. Stewart Campbell, Ph.D., chief executive officer, will present an overview of the company and take part in one-on-one meetings with institutional investors at the Jefferies Microbiome-based Therapeutics Summit on April 22, 2021.
  • The summit is a virtual event and the presentation will be accessible to conference registrants for 30 days.\nAxial Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of gut-targeted, small molecule therapeutics to treat neurological conditions and cancer.
  • Axial is advancing a pipeline of product candidates with lead clinical programs that address underlying pathology and resulting symptoms in Autism Spectrum Disorder (ASD) and Parkinson\xe2\x80\x99s Disease (PD).
  • For more information, visit https://axialtx.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210415005085/en/\n'

Asia Pacific Electronic Clinical Outcome Assessment Markets, 2019-2020 & 2021-2026 - ResearchAndMarkets.com

Wednesday, April 14, 2021 - 6:44pm

b'The "Asia Pacific Electronic Clinical Outcome Assessment Market By Delivery Mode, By End Use, By Country, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe China market dominated the Asia Pacific Pharma & Biotech Companies Market by Country in 2019, thereby, achieving a market value of $17.1 Million by 2026.\nWith an aim to gather patient data in a clinical trial, an eCOA solution is utilized.

Key Points: 
  • b'The "Asia Pacific Electronic Clinical Outcome Assessment Market By Delivery Mode, By End Use, By Country, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe China market dominated the Asia Pacific Pharma & Biotech Companies Market by Country in 2019, thereby, achieving a market value of $17.1 Million by 2026.\nWith an aim to gather patient data in a clinical trial, an eCOA solution is utilized.
  • The global electronic clinical outcome assessment (eCOA) solutions market is anticipated to witness consistent & high growth over the forecast years.
  • Hence, clinical outcome assessments (COAs) are constantly utilized to evaluate the treatments\' influence on several chronic diseases, and in some cases, these have a considerable role in the regulatory approval of drugs.
  • Although, the major restraints for the market growth are the huge cost of implementation & data privacy concerns.\nMarket Segments covered in the Report:\n'

Global Vasomotor Symptoms of Menopause (Hot Flashes) Disease Clinical Trials Review, H1 2021 Featuring 10 Key Players & Respective Trials - ResearchAndMarkets.com

Wednesday, April 14, 2021 - 4:34pm

b'The "Vasomotor Symptoms of Menopause (Hot Flashes) Disease - Global Clinical Trials Review, H1, 2021" clinical trials has been added to ResearchAndMarkets.com\'s offering.\n"Vasomotor Symptoms of Menopause (Hot Flashes) Disease - Global Clinical Trials Review, H1, 2021" provides an overview of Vasomotor Symptoms of Menopause (Hot Flashes) Clinical trials scenario.

Key Points: 
  • b'The "Vasomotor Symptoms of Menopause (Hot Flashes) Disease - Global Clinical Trials Review, H1, 2021" clinical trials has been added to ResearchAndMarkets.com\'s offering.\n"Vasomotor Symptoms of Menopause (Hot Flashes) Disease - Global Clinical Trials Review, H1, 2021" provides an overview of Vasomotor Symptoms of Menopause (Hot Flashes) Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Vasomotor Symptoms of Menopause (Hot Flashes).\nReport includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
  • Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).\nThe report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.\nReport provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status\nThe report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company\nThe report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment\nAids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials\nFacilitates clinical trial assessment of the indication on a global, regional and country level\n'